False-Positive 68Ga-Fibroblast Activation Protein-Specific Inhibitor Uptake of Benign Lymphoid Tissue in a Patient with Breast Cancer

Gundogan C., Guzel Y., Can C., Alabalik U., Komek H.

Clinical Nuclear Medicine, vol.46, no.8, 2021 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 46 Issue: 8
  • Publication Date: 2021
  • Doi Number: 10.1097/rlu.0000000000003594
  • Journal Name: Clinical Nuclear Medicine
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE
  • Keywords: F-18-FDG, Ga-68-FAPI, breast cancer, PET/CT, F-18-FDG PET/CT, GA-68-FAPI
  • Gazi University Affiliated: No


© Wolters Kluwer Health, Inc. All rights reserved.68Ga-fibroblast activation protein-specific inhibitor (FAPI)-04 PET/CT was performed in a patient with left lower outer quadrant breast cancer who had 18F-FDG PET/CT imaging. 68Ga-FAPI-04 PET/CT showed higher accumulation of radiotracer in primary tumor and axillary lymph nodes than 18F-FDG PET/CT. In addition, focal increased FAPI uptake was observed in another nodular lesion in the lower inner quadrant in the same breast, which was considered malignant. However, Tru-Cut biopsy of this lesion was reported as benign lymphoid tissue. This case showed that all FAPI accumulation in breast tissue should not be interpreted in favor of malignancy; histopathological confirmation is required.